Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Vor Biopharma
(NASDAQ:VOR)
Intraday
$1.88
0
[0.00%]
After-Hours
$1.88
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.88
0
[0.00%]
At close: Apr 23
$1.88
0
[0.00%]
PreMarket: 4:02PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Vor Biopharma Stock (NASDAQ:VOR)
Vor Biopharma Stock (NASDAQ: VOR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 23, 2024
Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Benzinga Newsdesk
-
18 hours ago
Friday, April 05, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Apr 5, 2024, 4:31PM
Friday, March 22, 2024
JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
Benzinga Newsdesk
-
Mar 22, 2024, 1:13PM
Thursday, March 21, 2024
Stifel Maintains Buy on Vor Biopharma, Lowers Price Target to $12
Benzinga Newsdesk
-
Mar 21, 2024, 9:39AM
Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Benzinga Newsdesk
-
Mar 21, 2024, 9:14AM
Oppenheimer Reiterates Outperform on Vor Biopharma, Lowers Price Target to $15
Benzinga Newsdesk
-
Mar 21, 2024, 9:02AM
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Benzinga Newsdesk
-
Mar 21, 2024, 6:44AM
Wednesday, March 20, 2024
Vor Biopharma: Q4 Earnings Insights
Benzinga Insights
-
Mar 20, 2024, 5:30PM
Vor Biopharma Expects To Report Further Engraftment And Protection Data From The VBP101 Clinical Trial In H2 2024
Benzinga Newsdesk
-
Mar 20, 2024, 4:34PM
Vor Biopharma Q4 2023 GAAP EPS $(0.39) Beats $(0.51) Estimate
Benzinga Newsdesk
-
Mar 20, 2024, 4:30PM
Thursday, January 18, 2024
Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Benzinga Newsdesk
-
Jan 18, 2024, 8:24AM
Wednesday, January 17, 2024
Vor Bio Doses First AML Patient With VCAR33
Benzinga Newsdesk
-
Jan 17, 2024, 4:02PM
Thursday, November 09, 2023
Vor Bio Presents Data Update On Trem-cel At HSCT Conference; Primary Neutrophil Engraftment Of Trem-cel Achieved In All Seven Patients Treated To Date
Benzinga Newsdesk
-
Nov 9, 2023, 4:49PM
Tuesday, November 07, 2023
Vor Biopharma Q3 EPS $(0.49) Misses $(0.47) Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 5:17PM
Thursday, November 02, 2023
Multiple Clinical And Preclinical Presentations At ASH 2023 Highlight Vor Bio's Novel eHSC And CAR-T Platform
Benzinga Newsdesk
-
Nov 2, 2023, 9:20AM
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 3, 2023, 2:37PM
Thursday, September 21, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 21, 2023, 12:08PM
Tuesday, September 19, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 19, 2023, 12:50PM
Monday, August 14, 2023
The Latest Analyst Ratings for Vor Biopharma
Benzinga Insights
-
Aug 14, 2023, 12:00PM
JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
Benzinga Newsdesk
-
Aug 14, 2023, 8:52AM
Friday, August 11, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Aug 11, 2023, 2:01PM
Wedbush Maintains Outperform on Vor Biopharma, Lowers Price Target to $11
Benzinga Newsdesk
-
Aug 11, 2023, 10:43AM
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Benzinga Newsdesk
-
Aug 11, 2023, 6:33AM
Thursday, August 10, 2023
Vor Bio Reports Q2 2023 Cash, Cash Equivalents $186.9M
Benzinga Newsdesk
-
Aug 10, 2023, 5:19PM
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Aug 10, 2023, 1:43PM
Tuesday, August 08, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Aug 8, 2023, 1:32PM
Thursday, July 06, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Jul 6, 2023, 12:58PM
Wednesday, July 05, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Jul 5, 2023, 12:43PM
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July
Lisa Levin
-
Jul 5, 2023, 8:51AM
Monday, June 12, 2023
What 11 Analyst Ratings Have To Say About Vor Biopharma
Benzinga Insights
-
Jun 12, 2023, 10:02AM
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Benzinga Newsdesk
-
Jun 12, 2023, 6:12AM
Friday, June 09, 2023
Vor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patients
Vandana Singh
-
Jun 9, 2023, 2:03PM
Vor Bio Announced Successful Primary Engraftment Of Trem-cel In First Five Acute Myeloid Leukemia Patients
Charles Gross
-
Jun 9, 2023, 7:38AM
Tuesday, May 16, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Benzinga Insights
-
May 16, 2023, 11:00AM
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Benzinga Newsdesk
-
May 16, 2023, 6:30AM
JonesTrading Initiates Coverage On Vor Biopharma with Buy Rating, Announces Price Target of $18
Benzinga Newsdesk
-
May 16, 2023, 5:05AM
Friday, May 12, 2023
Wedbush Reiterates Outperform on Vor Biopharma, Maintains $18 Price Target
Benzinga Newsdesk
-
May 12, 2023, 9:51AM
Thursday, May 11, 2023
Vor Biopharma: Q1 Earnings Insights
Benzinga Insights
-
May 11, 2023, 5:45PM
Vor Biopharma Q1 EPS $(0.43) Up From $(0.61) YoY
Happy Mohamed
-
May 11, 2023, 4:38PM
Friday, March 24, 2023
Dow Rises 50 Points; Oxford Industries Shares Plunge
Lisa Levin
-
Mar 24, 2023, 2:28PM
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Mar 24, 2023, 1:03PM
Where Vor Biopharma Stands With Analysts
Benzinga Insights
-
Mar 24, 2023, 1:01PM
Truist Securities Maintains Buy Rating for Vor Biopharma: Here's What You Need To Know
Benzinga Insights
-
Mar 24, 2023, 1:00PM
Truist Securities Maintains Buy on Vor Biopharma, Lowers Price Target to $16
Benzinga Newsdesk
-
Mar 24, 2023, 12:29PM
Vor Biopharma shares are trading higher after the company reported better-than-expected Q4 EPS results.
Benzinga Newsdesk
-
Mar 24, 2023, 10:37AM
Stifel Maintains Buy on Vor Biopharma, Lowers Price Target to $16
Benzinga Newsdesk
-
Mar 24, 2023, 10:21AM
Oppenheimer Reiterates Outperform on Vor Biopharma, Maintains $18 Price Target
Benzinga Newsdesk
-
Mar 24, 2023, 8:50AM
JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
Benzinga Newsdesk
-
Mar 24, 2023, 8:08AM
Baird Maintains Outperform on Vor Biopharma, Lowers Price Target to $22
Benzinga Newsdesk
-
Mar 24, 2023, 6:42AM
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Lowers Price Target to $17.5
Benzinga Newsdesk
-
Mar 24, 2023, 6:19AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch